Compare Citius Pharmaceuticals Inc (CTXR) vs Firy Inc. (FIRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Firy Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Firy Inc. trades at $12.09 (market cap $199.80M). The key difference: Firy Inc. is far larger — about 14.7× Citius Pharmaceuticals Inc's market cap, and Firy Inc. is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Firy Inc. for 13 Days on average.
| CTXR | FIRY | |
|---|---|---|
Market Cap | $13.62M | $199.80M |
Volume | 132,438 | 92,993 |
Sector | Health | Technology |
52-Week High | $1.82 | $13.10 |
52-Week Low | $0.48 | $2.28 |
Typical Hold Time | 16 Days | 13 Days |
Enterprise Value | $3.79M | $168.40M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
FIRY trades at $12.18, up 2.78% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $31.0 million but missed EPS expectations with a net loss. Despite a high gross margin of 87.76%, profitability remains challenged with negative net income margin and ROE. Recent developments include a $719 million legal victory and board appointment of Marc Lasry.
The outlook remains cautious due to persistent cash burn and negative earnings, though the legal win provides potential upside. Investment opportunity hinges on successful monetization of legal claims and operational turnaround. Key risks include ongoing cash flow deficits, competitive pressures, and uncertainty around debt collection from Papaya Gaming.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Firy Inc.
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →
